EGFR and non-small cell lung carcinoma: The expanding array of targeted pharmacotherapeutic agents approved for clinical use has significantly enhanced the management of patients with NSCLC with metastatic EGFR mutations, particularly those harboring the acquired EGFR T790M mutation, who show progression despite ongoing EGFR-TKI treatment [4,5].